The one thing I do know is that XMDC CEO Paul and Mr. Lee just need to knock these out one by one and the stock price will take care of itself imho.
*BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device.
*We expect to finalize this merger in the next thirty to sixty days. From October 1st....
*Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number
*The share structure of the company will remain in effect with no changes anticipated.
*Any changes we've recently made to the corporate structure are to effectuate this merger and any and all shares issued for this merger are subject to Rule 144 Restrictions.
*We strongly feel that our Authorized shares at this time are sufficient to handle our merger and capital raise needs. We feel it would be disadvantageous to do any sort of reverse split due to the potential sales of the BioHarp unit in the coming years. If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we've received, the company's market cap will be substantial
*Sell this device globally to healthcare organizations and countries looking to detect early signs of diseases that will save lives and lessen costs associated with treating these diseases.
*The BioHarp has gone through several revisions and is now ready to go into full production.
*Our goal is to get this device into the hands of physicians, veterinarians, and other professionals that understand the technology can detect, on a molecular level, inflammation that can lead to serious health problems.
*We will market this product aggressively and have already been contacted by several countries in Asia and Europe that are interested in making the BioHarp part of their national healthcare program.
*In short, this device can be used as an early diagnostic device by any country, healthcare company, managed care company, military, and in almost any other situation where an early diagnosis can assist in saving lives and lowering healthcare costs.
*Since the announcement of this merger, we have been working hard with Pink Sheets to become fully compliant with their reporting requirements. We should have this accomplished by week's end and hopefully have the Stop Sign removed from our company's profile
*Our goal is to move up to a greater exchange due to the potential sales that we anticipate the BioHarp will be doing globally very soon. We are working with our accountant and legal teams to ensure that we have everything in order so the migration to a higher exchange can be accomplished at the proper time.
*The BioHarp unit market potential stretches globally. There has been interest from several health departments globally to deploy the BioHarp to outlying village areas and major metropolitan healthcare clinics to utilize the BioHarp as an effective tool for pre-diagnosis on regular physical appointments. These countries will use the five sensor unit and the software will be integrated into their respective national healthcare databases.
*"In addition to the human markets, the BioHarp will be marketed to the pet and equine industries. The management at XTend has made several contacts with the veterinary market to utilize the BioHarp to scan dogs, cats, and other pets
*The equine industry itself can be very lucrative for the company in the future. The management at XTend has several thoroughbred trainers and owners they have spoken with about utilizing the BioHarp as part of a daily routine for racehorses to insure their training and subsequent earnings potential is not compromised....there are literally hundreds of racetracks with thousands of horses, each representing a significant investment to their owners.These scans would be done with the one sensor unit and would probably be sold and managed by our internal medical team at BioHarp UNI US. The potential trainers and owners would contract with us to scan the animals regularly; generating daily, weekly, and/or a monthly maintenance fee schedule for the company
*The revenue model for the BioHarp comes from both the hardware and software sales. The single sensor unit will sell for $5,000 US dollars and the five sensor unit will be $30,000. The software will be sold on a license agreement wherein BioHarp UNI US will charge $19.99 per month per patient license, thereby creating a continued revenue stream once the unit hardware is sold. Naturally, if we have groups that are purchasing thousands of units, we will have a discount structure to these monthly fees. With the patient potential in the millions, our revenue model will be very strong and consistent for years to come.
*Mr. Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend.
*The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger.
*We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company.
*While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company.
*Our intention is to market the product aggressively throughout Asia, the U.S. and Europe. To date, we've had over 7 inquiries from medical device companies looking to represent the BioHarp in 4 different countries globally
*BioHarp can be used to detect cellular inflammation in plants. Diseases in crops have risen dramatically over the years and the BioHarp can assist scientists in helping to determine the proper course of treatment in order to insure plants can sustain life. The global percussion in this area can be tremendous for the company.
News 
Market Data 
Discover 
